Using NGS, inflammatory breast cancer (IBC) exhibited clinically significant genetic alterations (CRGA) in genes like TP53, MYC, ERBB2, FGFR1, BRCA2, and PTEN. This information guides personalized treatment, transitioning from traditional chemotherapy to more targeted therapies, potentially enhancing efficacy and minimizing side effects [65]. Here, TP53 is linked to inflammatory breast carcinoma.